Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Alberto Sobrero et al.|The Lancet|2023Cited by 319
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Andrea Cercek, Salvatore Siena et al.|The Lancet Oncology|2023Cited by 244
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).Marwan Fakih, Andrew Scott Paulson, Kanwal Raghav et al.|Journal of Clinical Oncology|2021Cited by 74